Molly Hoult

Senior Principal


Brand Plan Development, Commercialization, Digital Health, Digital Medicine, Digital Technology, Pricing, Reimbursement & Market Access, Revenue Management

Molly Hoult is an expert at helping life science companies build value by meeting market needs better than their competitors. She digs deep into market and competitive dynamics to determine how best to develop a product, enter a market, and expand into new areas to accelerate growth. Delivering actionable recommendations to management, boards of directors, and investors, Molly has been a strategic partner to biopharma, diagnostics, and device companies of all sizes for more than 15 years. Her experience spans commercial strategy, new product planning, market research, business and corporate development, project management, and more across major therapeutic areas and US and ex-US markets.

Before joining the team, Molly was senior vice president in the Life Science Practice at Fletcher Spaght, Inc., where she had a strong track record of achieving high client satisfaction, delivering projects on time and on budget, and mentoring junior staff. Over her decade there, Molly led many cross-functional teams in conducting primary market research and analyses of market size, growth, trends, competitive landscapes, receptivity, pricing, reimbursement, segmentation, distribution options, revenue analysis, and valuation. Prior to Fletcher Spaght, Molly was an independent consultant providing strategic planning and business development services to life science companies; and a senior vice president at Blue Heron Biotechnology, where she launched a DNA synthesis service and built the organization’s commercial team. Molly has also held senior business development positions at XCyte Therapies and ZymoGenetics (now part of Bristol-Myers Squibb) and has been a product manager at NeoPath (now part of BD Diagnostics) and Amgen.

Molly holds an MBA from Stanford Graduate School of Business, where she was an Arjay Miller Scholar, and a bachelor of arts with honors in biology and a minor in environmental studies from Dartmouth College.

Articles by Molly Hoult

How to Determine Price and Global Launch Sequence in a Post-COVID World

The globe is facing a multitude of governing and legislative changes that will directly affect pharma and pricing in coming years, with many of these changes initiated by the pandemic. As countries become increasingly interconnected, decisions in one pharmaceutical market will have ripple effects globally.

Key Factors to Obtaining Reimbursement for Digital Therapeutics in the U.S.

While wellness apps have been successful in a direct-to-consumer model, many digital therapeutics (DTx) providers are working to obtain reimbursement from U.S. payers. In a heterogenous payer ecosystem, the key question is how to obtain broad payer coverage and reimbursement with a low out-of-pocket cost to the patient. Early prescription DTx companies have explored a […]

How Pharma Can Meet Commercialization and Marketing Challenges During COVID-19

With a resurgence of COVID-19 cases underway and a second wave of infections on the horizon, the health and economic threats the pandemic poses are not going away any time soon. The crisis has triggered clinical trial delays for many manufacturers of pharmaceutical products, while others have rallied around the COVID-19 pandemic, with as many […]

Interested in scheduling a meeting or speaking event?

Contact Us

  • This field is for validation purposes and should be left unchanged.